Grant: Master's Award: Canada Graduate Scholarships
University of British Columbia
$17,500.00
Intra-tumoural Delivery of Anti-Cancer Drugs
EF 2016-17
Résumé
The intent of this research is to develop a drug delivery platform that confines drug release to the tumour, and only when triggered by an external source of energy. Liposomes will be utilized to sequester the drug payload during circulation and to concentrate the encapsulated drug in the tumour perivascular space. Gold nanoparticles attached to the liposomes will enable the conversion of externally applied optical energy into localized heat, which in turn will disrupt the liposome bilayer to release the encapsulated anti-cancer drug. The following project milestones will be undertaken in this research proposal: (i) Gold-liposome nanoparticles will be prepared and characterized; when these nanoparticles are subsequently loaded with the drug, they will be further assessed for their stability and their ability to retain the encapsulated drug payload. (ii) The bio-distribution of the gold-liposome nanoparticles will be evaluated in vivo with tumour-bearing mice to determine the particles' circulation time and accumulation characteristics. (iii) The drug release characteristics of the radiated drug-loaded gold-liposome nanoparticles will be assessed and optimized for maximum drug release; additionally, the levels of cell death resulting from the combined chemo-radiation therapy will be evaluated. (iv) Finally, the utility of the optimized drug-loaded nanoparticles will be assessed for intra-tumoural drug delivery controlled by combined chemo-radiotherapy in vivo with tumour-bearing mice. The overall therapeutic implication of this proposed solution is that curative drug doses would be achieved in the tumour, but with lower systemic toxicities. In turn, this will improve the outcomes and quality-of-life for patients.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
367356
Name
van Ballegooie Courtney E
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Intra-tumoural Delivery of Anti-Cancer Drugs
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Chemotherapy; Drug Delivery; Encapsulation; Gold Nano Particles; Improved Outcomes; Intra-Tumoural; Liposomes; Quality-Of-Life; Radiation Therapy
Abstract
The intent of this research is to develop a drug delivery platform that confines drug release to the tumour, and only when triggered by an external source of energy. Liposomes will be utilized to sequester the drug payload during circulation and to concentrate the encapsulated drug in the tumour perivascular space. Gold nanoparticles attached to the liposomes will enable the conversion of externally applied optical energy into localized heat, which in turn will disrupt the liposome bilayer to release the encapsulated anti-cancer drug. The following project milestones will be undertaken in this research proposal: (i) Gold-liposome nanoparticles will be prepared and characterized; when these nanoparticles are subsequently loaded with the drug, they will be further assessed for their stability and their ability to retain the encapsulated drug payload. (ii) The bio-distribution of the gold-liposome nanoparticles will be evaluated in vivo with tumour-bearing mice to determine the particles' circulation time and accumulation characteristics. (iii) The drug release characteristics of the radiated drug-loaded gold-liposome nanoparticles will be assessed and optimized for maximum drug release; additionally, the levels of cell death resulting from the combined chemo-radiation therapy will be evaluated. (iv) Finally, the utility of the optimized drug-loaded nanoparticles will be assessed for intra-tumoural drug delivery controlled by combined chemo-radiotherapy in vivo with tumour-bearing mice. The overall therapeutic implication of this proposed solution is that curative drug doses would be achieved in the tumour, but with lower systemic toxicities. In turn, this will improve the outcomes and quality-of-life for patients.
Competitiondate
201612
Approvedterm2
1 yr 0 mth
Pinamesdelim
van Ballegooie, Courtney E
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~